IRVINE, CA--(Marketwire - April 19, 2011) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that in May 2011 its chairman and chief executive officer, Michael A. Mussallem, will begin exercising stock options that are near expiration under a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934.
The plan, which Mussallem adopted in November 2010, will provide a vehicle for him to exercise Edwards stock options due to expire in May 2012, and provides for the exercise and sale of up to 70,000 shares per month. Under this plan, stock sales are intended to be spread evenly over an extended period of time. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information.
Mussallem is in full compliance with the company’s stock ownership guidelines for its executive officers. Under these guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plan, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under this plan will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission (SEC). The Form 4 filings will also be posted on Edwards’ investor relations Web site at http://www.edwards.com/InvestorRelations.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.
Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.
Media Contact:
Amanda C. Fowler
949-250-5070
Investor Contact:
David K. Erickson
949-250-6826
